Fulgent Genetics Inc. Releases Transcript for Q1 2025 Earnings Call Event

Reuters

昨天

<a href="https://laohu8.com/S/FLGT">Fulgent Genetics Inc.</a> Releases Transcript for Q1 2025 Earnings Call Event

Fulgent Genetics Inc. recently published the transcript of their Q1 2025 earnings call, held on May 2, 2025. The event was attended by key company figures, including CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, with Melanie Solomon from Investor Relations facilitating the call. During the call, the management highlighted the company's strong performance in the first quarter of 2025, showcasing year-over-year growth in their Laboratory Services. CEO Ming Hsieh expressed optimism, stating, "We are pleased with our first-quarter results, having shown year-over-year growth in Laboratory Services, and we are seeing great, good momentum in 2025." Additionally, the company discussed the progress of their Therapeutic Development pipeline, emphasizing that their first clinical candidate, FID-007, is on track with its Phase 2 clinical trial. The full transcript can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on May 03, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2532386458"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532386458\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2532386458?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-03 09:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532386458","market":"us","top_or_hot":-1,"title":"Fulgent Genetics Inc. Releases Transcript for Q1 2025 Earnings Call Event","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FLGT\">Fulgent Genetics Inc.</a> Releases Transcript for Q1 2025 Earnings Call Event\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fulgent Genetics Inc. recently published the transcript of their Q1 2025 earnings call, held on May 2, 2025. The event was attended by key company figures, including CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, with Melanie Solomon from Investor Relations facilitating the call. During the call, the management highlighted the company's strong performance in the first quarter of 2025, showcasing year-over-year growth in their Laboratory Services. CEO Ming Hsieh expressed optimism, stating, \"We are pleased with our first-quarter results, having shown year-over-year growth in Laboratory Services, and we are seeing great, good momentum in 2025.\" Additionally, the company discussed the progress of their Therapeutic Development pipeline, emphasizing that their first clinical candidate, FID-007, is on track with its Phase 2 clinical trial. The full transcript can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on May 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fulgent Genetics Inc. Releases Transcript for Q1 2025 Earnings Call Event</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFulgent Genetics Inc. Releases Transcript for Q1 2025 Earnings Call Event\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-03 09:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FLGT\">Fulgent Genetics Inc.</a> Releases Transcript for Q1 2025 Earnings Call Event\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fulgent Genetics Inc. recently published the transcript of their Q1 2025 earnings call, held on May 2, 2025. The event was attended by key company figures, including CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, with Melanie Solomon from Investor Relations facilitating the call. During the call, the management highlighted the company's strong performance in the first quarter of 2025, showcasing year-over-year growth in their Laboratory Services. CEO Ming Hsieh expressed optimism, stating, \"We are pleased with our first-quarter results, having shown year-over-year growth in Laboratory Services, and we are seeing great, good momentum in 2025.\" Additionally, the company discussed the progress of their Therapeutic Development pipeline, emphasizing that their first clinical candidate, FID-007, is on track with its Phase 2 clinical trial. The full transcript can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on May 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FLGT","symbol_name":"Fulgent Genetics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250503:nNDLbwkDF9:1","article_id":"2532386458","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532386458","pubTimestamp":1746234431,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Fulgent Genetics Inc. recently published the transcript of their Q1 2025 earnings call, held on May 2, 2025. The event was attended by key company figures, including CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, with Melanie Solomon from Investor Relations facilitating the call. During the call, the management highlighted the company's strong performance in the first quarter of 2025, showcasing year-over-year growth in their Laboratory Services. CEO Ming Hsieh expressed optimism, stating, \"We are pleased with our first-quarter results, having shown year-over-year growth in Laboratory Services, and we are seeing great, good momentum in 2025.\" Additionally, the company discussed the progress of their Therapeutic Development pipeline, emphasizing that their first clinical candidate, FID-007, is on track with its Phase 2 clinical trial. The full transcript can be accessed through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"FLGT":"Fulgent Genetics Inc."},"translate_title":"Fulgent Genetics Inc.发布2025年第一季度收益看涨期权活动记录","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FLGT":0.9},"content_text":"Fulgent Genetics Inc. Releases Transcript for Q1 2025 Earnings Call Event\n    \n\n        Fulgent Genetics Inc. recently published the transcript of their Q1 2025 earnings call, held on May 2, 2025. The event was attended by key company figures, including CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, with Melanie Solomon from Investor Relations facilitating the call. During the call, the management highlighted the company's strong performance in the first quarter of 2025, showcasing year-over-year growth in their Laboratory Services. CEO Ming Hsieh expressed optimism, stating, \"We are pleased with our first-quarter results, having shown year-over-year growth in Laboratory Services, and we are seeing great, good momentum in 2025.\" Additionally, the company discussed the progress of their Therapeutic Development pipeline, emphasizing that their first clinical candidate, FID-007, is on track with its Phase 2 clinical trial. The full transcript can be accessed through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on May 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}